Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

REYKJAVIK, Iceland , Jan. 29, 2024 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and the USA published a study today in Nature Structural & Molecular Biology titled "Variant in the synaptonemal complex protein SYCE2 associates with pregnancy loss through effects on recombination". While it is well established that chromosomal abnormalities are a major cause of miscarriages the biology behind pregnancy losses with or without chromosomal errors is not well understood.

deCODE genetics: A sequence variant that increases risk of pregnancy loss

Amgen is treating cancers using a new therapeutic modality. It's planning on producing a few more therapies in the same vein.

Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock.

In the latest trading session, Amgen (AMGN) closed at $310.26, marking a +1.56% move from the previous day.

Amgen (AMGN) Outperforms Broader Market: What You Need to Know

Altimmune

Biohaven Pharmaceutical Hld

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs

Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amgen Inc. (AMGN) Soars to 52-Week High, Time to Cash Out?

Cigna

Elevance Health Inc

Humana

Incyte

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp. NASDAQ: PODD and Cigna Group NYSE: CI.

5 top healthcare stocks for earnings growth in 2024

Medtronic

Altria

PepsiCo

Walmart

Dividend growth stocks have outclassed most other asset types since the start of the 20th century. Here is an overview of five of the best dividend growers on the planet.

5 Magnificent Dividend Growth Stocks to Buy and Hold Forever

Amgen's stock price has surged, driven by strategic acquisitions, a diverse medical portfolio, and a focus on AI innovation, positioning it for substantial long-term growth. Amgen's strong performance stems from its diverse presence in general medicine, oncology, inflammation, and a thriving rare disease business unit. It also sees opportunities in biosimilars, obesity drugs, and AI capabilities, paving the road for consistent growth.

Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks

Amgen (AMGN) reachead $307.81 at the closing of the latest trading day, reflecting a +1.09% change compared to its last close.

Here's Why Amgen (AMGN) Gained But Lagged the Market Today

The U.S. health regulator said on Friday it has revised the prescribing information on Amgen's drug to treat bone loss to include a boxed warning related to risk of severely low calcium level in certain patients.

US FDA revises labeling on Amgen's drug to treat bone loss

Centene

Cencora Inc

Catalent

Gilead Sciences

Merck

Moderna

Regeneron Pharmaceuticals

Viatris

The sector has seen one of the best starts to the year in decades, Goldman says.

10 Healthcare Stocks That Are Heating Up

Two sets of reliable stock market cycles have topped. Technically, the market does not appear as weak as expected.

Stocks This Week: Buy The Biotech Stocks: Amgen And Gilead

argenx

BeiGene

CRISPR Therapeutics

Immunovant Inc

Biotech has been out of favor among investors for over two years. The sector could be on the verge of a trend reversal because of multiple tailwinds.

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

AstraZeneca

Eli Lilly

Novo Nordisk

The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.

FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts

Boston Scientific

Stryker

Here are three stocks in the health care sector that could provide further upside potential based on their improving technical characteristics.

Health care stocks are back in favor and these 3 names could lead the rally, according to the charts

Dow Inc

“The Dogs of the Dow” system involves purchasing the index's 10 stocks with the highest dividend yields at the end of each year. Using the technique has a few major advantages.

Dogs of the Dow: January's Top 3 Picks to Buy for Big Gains

Xeris Biopharma Holdings

Xeris Biopharma Holdings (NASDAQ:XERS) announced an exclusive worldwide license agreement with Amgen for the development, manufacturing, and commercialization of a subcutaneous formulation of teprotumumab using Xeris' XeriJect technology.   The collaboration aims to address Thyroid Eye Disease (TED), a severe, progressive, and potentially vision-threatening rare autoimmune disorder.

Xeris Biopharma inks exclusive worldwide license agreement with Amgen for XeriJect in thyroid eye disease

Up 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It's very early, but the sector has outpaced all other 10 economic groups since the ball dropped in Times Square.

3 health care stocks off to strong starts in 2024

Apple

AbbVie

Advanced Micro Devices

Amazon

ASML Hld

Broadcom

Blackrock Inc

FactSet Research Systems

Alphabet

Home Depot

Lowe's

Mastercard

MSCI

Microsoft

NVIDIA

Realty Income Corp

Prologis

Invesco QQQ

Schwab US Dividend Equity ETF

SPDR S&P 500 ETF Trust

Tesla

How To Build A Dividend Growth Portfolio As A 'Young Investor' With $100,000

Amgen Inc. (AMGN) Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024 (Transcript)

Dow Jones biotech leader Amgen extended its breakout gains, while Ozempic maker Novo Nordisk is in buy range past its latest buy point.

Dow Jones Leader Amgen Extends Gains Past Buy Point; Ozempic Maker Novo Nordisk Breaks Out

Recursion Pharmaceuticals

Nvidia Corp. NVDA, +4.72% is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships Monday with Amgen Inc. AMGN, +1.26% and Recursion Pharmaceuticals Inc. RXRX, +3.61%.

Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships

Cisco Systems

Chevron

Johnson & Johnson

The 2024 Dogs of the Dow are particularly homely hounds—which means we're talking big dividends.

Dogs Of The Dow 2024: 10 Blue-Chip Dividend Payers

News for Amgen Stock (AMGN)